ProSeed Venture Capital Fund (TASE:PRSD) portfolio company PerfAction Technologies Ltd. has obtained US Food and Drug Administration (FDA) marketing approval for its Airgent subdermal drug delivery system.
PerfAction develops minimal invasive aesthetic systems and solutions. Airgent is based on the company's patent-pending SubDermal Minimal Surgery (SMS) technology for drug delivery through the skin without the use of needles. The product prevents pain and significantly reduces the side effects of other technologies.
Airgent is intended for surgical and aesthetic treatments to repair scar tissue, renew collogen, and resolve other problems.
ProSeed owns 24.2% of Airgent. Other investors include Adina Makover, Uriel Halavee, and former Lumenis CEO Yacha Sutton. The company was founded by Sutton, Radiancy co-founders Zion Ezer and Pinchas Shalev, and Eyal Bar-Or, who serves as CEO.
Published by Globes [online], Israel business news - www.globes-online.com - on February 19, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009